Compare PXED & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | GERN |
|---|---|---|
| Founded | 1976 | 1990 |
| Country | United States | United States |
| Employees | 3400 | 258 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 821.1M |
| IPO Year | N/A | N/A |
| Metric | PXED | GERN |
|---|---|---|
| Price | $30.16 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $44.29 | $2.17 |
| AVG Volume (30 Days) | 71.6K | ★ 14.2M |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | $26.91 |
| Revenue Next Year | $4.49 | $43.75 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $1.04 |
| 52 Week High | $38.19 | $2.01 |
| Indicator | PXED | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 32.94 |
| Support Level | $28.40 | $1.24 |
| Resistance Level | $30.85 | $1.29 |
| Average True Range (ATR) | 1.37 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 57.47 | 10.42 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.